AstraZeneca lists shares directly on the New York Stock Exchange
Updated
Updated · The Wall Street Journal · May 11
AstraZeneca lists shares directly on the New York Stock Exchange
15 articles · Updated · The Wall Street Journal · May 11
The UK drugmaker said 2025 revenue reached $58.74 billion and it is targeting $80 billion by 2030, with US sales expected to rise to 50% of total revenue.
Finance chief Aradhana Sarin said more than 25 medicines could each generate over $1 billion by decade-end, spanning oncology, rare diseases and weight-loss treatments.
AstraZeneca is backing growth with AI-assisted drug development, heavy R&D spending and manufacturing investment, including a $1.5 billion Singapore facility due to start operating in 2029.
Can AstraZeneca's drug pipeline outpace its looming patent cliff and formidable weight-loss market rivals?
Is AstraZeneca’s aggressive push into AI creating a cybersecurity risk that could derail its $80 billion goal?
AstraZeneca’s Direct NYSE Listing: $291B Market Cap Move Redefines Global Investor Access
Overview
AstraZeneca made a major strategic move by directly listing its ordinary shares on the New York Stock Exchange (NYSE) on February 2, 2026, ending its previous American Depositary Shares (ADS) program on Nasdaq. This transition was part of a shareholder-approved plan to create a harmonized global listing structure, providing a unified trading platform across major international exchanges. By eliminating the need for a depositary bank, AstraZeneca simplified trading for investors and removed recurring custody and dividend fees. This change reflects AstraZeneca’s vision to better serve its global presence and strengthen its position in the international pharmaceutical industry.